Dr. Syeda Rubina Inamdar, MD

Dr. Inamdar practices at Mercy Medical Group, a Service of Dignity Health Medical Foundation in Elk Grove, California.

Dr. Inamdar's NPI, 1316981905, was assigned on June 15, 2006. Dr. Inamdar graduated from Feinberg School of Medicine in 1997. Dr. Inamdar holds California license A100882.

Dr. Inamdar's primary practice is Mercy Medical Group, a Service of Dignity Health Medical Foundation, at 9394 Big Horn Blvd, Elk Grove, CA 95758 in Sacramento County. The practice phone is (916) 733-3397.

Dr. Inamdar's primary practice is Mercy Medical Group, a Service of Dignity Health Medical Foundation in Elk Grove, California. The medical group on file is Mercy Medical Group. Dmand AI also links Dr. Inamdar to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Inamdar practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Inamdar's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Inamdar is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Inamdar's licenses on file in 2 states: California and Ohio.

Dmand AI lists acute sinusitis, asthma, chronic nasal allergies, chronic sinusitis and hives among the conditions Dr. Inamdar treats.

CMS data shows 1,749 Medicare services from Dr. Inamdar across 8 procedure codes in 2024, for 109 Medicare patients. Medicare paid $22,757 for them. Every service was in an office.

CMS counts 109 Medicare patients who saw Dr. Inamdar in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 33% are also on Medicaid. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Inamdar's median patient age at 41, with 60% women.

In 2024, Dr. Inamdar wrote 1,166 Medicare Part D claims for 182 patients. 54% of them were for generic drugs. CMS names the drug for 979 of them, across 27 drugs with 11 or more claims each, at $808,852 in total drug cost. In 2023, CMS named 841 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Inamdar for performance year 2024, reported through an alternative payment model (APM). Dr. Inamdar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Inamdar as offering telehealth.

CMS Open Payments shows 13 general payments to Dr. Inamdar from 8 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 98% of the total. Sanofi and Genzyme US Companies paid the most, $166.

Dr. Inamdar graduated from Feinberg School of Medicine in 1997. Dr. Inamdar is a member of AAAAI.

Dr. Inamdar is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.